BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other research firms also recently issued reports on NRXP. D. Boral Capital restated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, March 16th. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. HC Wainwright boosted their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Ascendiant Capital Markets restated a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NRx Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Stock Up 13.1%

NRXP opened at $2.41 on Tuesday. The firm has a market cap of $79.70 million, a PE ratio of -1.73 and a beta of 1.97. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $2.44. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Monday, March 23rd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.28. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $7.53 million. On average, equities research analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in NRXP. Geode Capital Management LLC increased its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the 3rd quarter valued at $39,000. One Wealth Management Investment & Advisory Services LLC boosted its holdings in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. AdvisorShares Investments LLC boosted its holdings in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares during the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals News Roundup

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: Company pursuing both ANDA (generic) and NDA (new drug) pathways for NRX‑101, signaling potential for near‑term commercial opportunities and a dual regulatory strategy that could expand addressable markets if either filing succeeds. NRx Pharmaceuticals (NRXP) looks to score double with ANDA and NDA filings for NRX-101
• Positive Sentiment: Q4 report delivered an EPS beat (reported $0.19 vs. consensus -$0.09), which likely surprised traders and helped lift sentiment despite mixed top‑line results. NRx Pharmaceuticals earnings / conference call
• Positive Sentiment: Two firms (D. Boral Capital and BTIG) reaffirmed “buy” ratings with high price targets ($34 and $25), which can amplify buying interest and momentum in a small‑float name. Benzinga
• Positive Sentiment: Full‑year 2025 update highlighted reduced operating expenses, $7.8M cash at year‑end and management’s view that current resources + revenues/ATMs should support operations through 2026 — improving near‑term runway visibility. NRx Reports Full‑Year 2025 Results
• Neutral Sentiment: Full Q4 2025 earnings call transcript is available for detail and could shape investor views depending on management guidance and Q&A. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Multiple short‑interest reports for March show zero shares / NaN changes — likely a data/reporting error. Short‑interest info is currently unreliable and shouldn’t be over‑interpreted until corrected.
• Negative Sentiment: Revenue for the quarter ($0.98M) materially missed consensus (~$7.5M), a notable weakness versus estimates that could temper the EPS beat’s positive effect. Press Release / Full Results
• Negative Sentiment: Analyst consensus still models a negative EPS for the year (group forecast ~-1.75), implying continued expectations for losses absent material commercial progress.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.